Market Cap: $1.72B
II
Intellia Therapeutics, Inc.
NTLA
NASDAQ (NASDAQ Global Market)USD
Market Cap: $1.72B
Intellia Therapeutics (Ticker: NTLA) has made significant strides in the biotechnology field with the promising results of its Phase 3 HAELO trial for the CRISPR-based therapy lonvo-z, aimed at treati…
Intellia Therapeutics advances the frontiers of genetic medicine with its CRISPR-based therapy, lonvo-z, which targets hereditary angioedema. The company is set to present significant phase 3 data at…
Intellia Therapeutics (Ticker: NTLA) is set to present pivotal phase 3 data related to its innovative CRISPR-based therapy, lonvo-z, designed to treat hereditary angioedema. This therapy offers a grou…
Intellia Therapeutics achieves critical milestones in its clinical programs that enhance its position in the biotech industry, particularly concerning its innovative CRISPR technology designed to trea…
Intellia Therapeutics (Ticker: NTLA) is making significant strides in gene editing therapies, especially with recent developments regarding its inherited angioedema treatment, lonvo-z. The company ann…
Avaí Bio Positions Itself as a Leader in Anti-Aging Therapy Development Avaí Bio, Inc. is making strides in the burgeoning anti-aging therapy market, specifically through its work on the Klotho anti-a…
A New Frontier in Anti-Aging: Avaí Bio's Commitment to Cell-Based Therapies Avaí Bio, Inc., a biotechnology company specializing in cell-based therapies for age-related conditions, is strategically po…
Intellia Therapeutics: Pioneering Innovations in Gene Editing Intellia Therapeutics continues to lead the charge in the rapidly evolving field of genetic medicine, developing pioneering CRISPR-based t…
Intellia Therapeutics: Pioneering Advances in CRISPR-Based Therapies Intellia Therapeutics is on the brink of announcing its quarterly earnings, scheduled for February 26, 2026, as anticipation builds…
Intellia Therapeutics Gears Up for Critical Earnings Announcement in February 2026 As Intellia Therapeutics approaches its quarterly earnings announcement scheduled for February 26, 2026, the company’…
Intellia Therapeutics: Pioneering Gene Editing Solutions Set for Impending Earnings Report Intellia Therapeutics (NASDAQ: NTLA), a leader in CRISPR-based therapies, approaches its quarterly earnings a…
Strategic Shift in Genomic Investment: A New Era for Biotechnology Cathie Wood, the CEO of ARK Invest, is making headlines with a notable shift in her investment strategy, signaling her anticipation o…
Intellia Therapeutics: Navigating Innovation Amid Market Complexity Intellia Therapeutics is at the forefront of the biotechnology industry, focusing on groundbreaking CRISPR-based therapies aimed at…
Intellia Therapeutics: Navigating the Complex Landscape of Genetic Therapies Intellia Therapeutics is at the forefront of biotechnology, particularly with its innovative CRISPR-based therapies aimed a…
Intellia Therapeutics: Advancing Gene Editing Technology Amid Market Volatility Intellia Therapeutics, a leader in the field of gene editing, continues to push the boundaries of CRISPR technology to d…
Intellia Therapeutics: Pioneering Advances in Gene Editing Technology Intellia Therapeutics is at the forefront of the biopharmaceutical industry, focusing on the development of innovative gene editin…
Developments in Gene Editing: Intellia Therapeutics' Promising Advances Intellia Therapeutics continues to make significant strides in the field of gene editing, particularly with its innovative CRISP…
Intellia Therapeutics Faces Regulatory Setback Amid FDA Clinical Hold Intellia Therapeutics Inc. has encountered a significant regulatory hurdle as the U.S. Food and Drug Administration (FDA) places a…
Intellia Therapeutics Faces Critical Challenge in Clinical Trials Intellia Therapeutics Inc. is currently navigating a significant setback as it announces a temporary halt in patient dosing and screen…
Intellia Therapeutics Faces Critical Setback in Clinical Trials Intellia Therapeutics Inc. recently announces a temporary halt in patient dosing and screening for its Phase 3 MAGNITUDE and MAGNITUDE-2…
Intellia Therapeutics Faces Critical Setback in Clinical Trials Intellia Therapeutics Inc. is currently navigating a significant challenge following its recent decision to temporarily pause patient do…
Intellia Therapeutics: Advancements in Gene Editing Technology In the rapidly evolving field of biotechnology, Intellia Therapeutics continues to make significant strides in gene editing technologies,…
Intellia Therapeutics: Advancements in Gene Editing Technology Intellia Therapeutics is making significant strides in the field of gene editing, particularly with its innovative use of CRISPR technolo…
Intellia Therapeutics: Navigating Diverse Analyst Sentiment on Gene-Editing Innovations Intellia Therapeutics is currently in the spotlight as six analysts provide a range of opinions on the company's…
Intellia Therapeutics: Navigating the Complexities of Gene-Editing Innovations In the competitive landscape of biotechnology, Intellia Therapeutics stands out for its innovative gene-editing technolog…